Posts Tagged ‘drugs’

Costly drugs | February 27, 2017 Issue – Vol. 95 Issue 9 | Chemical & Engineering News

March 25, 2017

Pushback on costly #drugs
http://CEN.acs.org/articles/95/i9/Pushback.html Table of signpost meds: $80k Sovaldi hep. C treatment, $14k/yr for PCSK9 inhibitor Repatha

Has Theraflu been discontinued? | Yahoo Answers

November 13, 2015

https://answers.yahoo.com/question/index?qid=20121118202232AAzmnTK

https://en.wikipedia.org/wiki/Theraflu

One big myth about medicine: We know how drugs work

August 8, 2015

Big myth about medicine: We know how #drugs work
http://www.washingtonpost.com/blogs/wonkblog/wp/2015/07/23/one-big-myth-about-medicine-we-know-how-drugs-work “If you only half-know something, you can appreciate serendipity”
QT:{{“

If you think you’re too smart and you only do what is scientifically indicated, there’s always going to be something, ‘Oh my God, we never thought of that!’” Haber said. “If you half-know what you’re doing, then you’re better prepared to understand or appreciate discoveries that are serendipitous in some way.”

A 2011 study reviewed a decade worth of drug approvals found that of 75 drugs that worked in a completely new way, 28 came from the more old-fashioned method of screening drugs against cells or animals, and 17 were built from detailed understanding of how the disease worked. David Swinney of the Institute for Rare and Neglected Diseases Drug Discovery said that despite the fact that far more resources are devoted to developing drugs by focusing on targets, the older method of screening has been more productive by his analysis.”
“}}

Why Are So Few Blockbuster Drugs Invented Today?

November 23, 2014

Why So Few Blockbuster #Drugs Invented Today? (Eroom’s law) http://www.nytimes.com/2014/11/16/magazine/why-are-there-so-few-new-drugs-invented-today.html Short answer: use of genomics v traditional pharmacology

QT:{{"
“If you read them now, the claims made for genomics in the 1990s sound
a bit like predictions made in the 1950s for flying cars and
anti-gravity devices,” Jack Scannell, an industry analyst, told me.
But rather than speeding drug development, genomics may have slowed it
down. So far it has produced fewer returns on greater investments.
Scannell and Brian Warrington, who worked for 40 years inventing drugs
for pharmaceutical companies, published a grim paper in 2012 that
showed the plummeting efficiency of the pharmaceutical industry. They
found that for every billion dollars spent on research and development
since 1950, the number of new drugs approved has fallen by half
roughly every nine years, meaning a total decline by a factor of 80.
They called this Eroom’s Law, because it resembled an inversion of
Moore’s Law (the observation, first made by the Intel co-founder
Gorden E. Moore in 1965, that the number of transistors in an
integrated circuit doubles approximately about every two years).

That’s not to say that target-based drug discovery, informed by
genomics, hasn’t had its share of spectacular successes. Gleevec, used
since 2001 to treat chronic myelogenous leukemia (C.M.L.) and a
variety of other cancers, is often pointed to as one of the great
gene-to-medicine success stories. Its design followed logically from
the identification of an abnormal protein caused by a genetic glitch
found in almost every cancer cell of patients with C.M.L.

Many of the drugs developed through target-based discovery, however,
work for only single-mutation diseases affecting a tiny number of
people. Seventy percent of new drugs approved by the F.D.A. last year
were so-called specialty drugs used by no more than 1 percent of the
population. The drug Kalydeco, for instance, was approved in 2012 for
people with a particular genetic mutation that causes cystic fibrosis.
But only about 1,200 people in the United States have the mutation it
corrects.
"}}

Ian Parker: The Search for a Blockbuster Insomnia Drug : The New Yorker

December 23, 2013

The Search for a Blockbuster Insomnia #Drug: from biochemical innovation to dosing gamesmanship (1/2)
http://www.newyorker.com/reporting/2013/12/09/131209fa_fact_parker MT @jekbradbury

.@jekbradbury Bizarre ending to story with $MRK arguing against efficacy of low-dose #suvorexant promoted by hyper-cautious FDA (2/2)

Inside Pfizer’s palace coup – Fortune Features

April 8, 2012

http://features.blogs.fortune.cnn.com/2011/07/28/pfizer-jeff-kindler-shakeup/

Drug data reveal sneaky side effects : Nature News & Comment

March 18, 2012

http://www.nature.com/news/drug-data-reveal-sneaky-side-effects-1.10220 [clip popsci]

Trials and Errors: Why Science Is Failing Us | Magazine

January 14, 2012

correlation v causation
http://www.wired.com/magazine/2011/12/ff_causation/all/1